Abstract:Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular events. This study evaluated the relationship between Lp(a) and high-risk attributes by coronary computed tomography angiography as well as their prognostic value. Lp(a) and coronary computed tomography angiography from 377 consecutive patients at Zhongshan Hospital (Shanghai, China) were evaluated. High-risk attributes were defined as high-risk morphological attributes (low attenuation plaque, positive remodeling, napkin-ring sign, spotty calcification, minimum lumen area <4 mm 2 , or plaque burden [ratio between cross-sectional plaque area at the site of maximum stenosis and cross-sectional vessel area] ≥70%); inflammatory attribute represented by fat attenuation index; high-risk physiological attributes [lesion-specific ischemia defined by fractional flow reserve by coronary computed tomography angiography ≤0.8, physiologic diffuseness defined by fractional flow reserve by coronary computed tomography angiography pullback pressure gradient]. Total plaque volume in mm 3 was also quantified. Quintiles or binary classification of Lp(a) levels were used to evaluate its relationships with plaque features and clinical outcomes with ANOVA, Cox models, and log-rank tests, as appropriate. The major adverse cardiovascular event included cardiovascular death, nonfatal myocardial infarction, and target vessel revascularization. Lp(a) was significantly associated with total plaque volume ( P =0.004), fat attenuation index ( P =0.031), and fractional flow reserve by coronary computed tomography angiography pullback pressure gradient ( P =0.038). Patients with a high Lp(a) level had a higher total plaque volume (393.3 mm 3 versus 293.9 mm 3 , P <0.001), lower pullback pressure gradient (0.62 versus 0.69, P =0.023), higher fat attenuation index (−70.5HU versus −73.9HU, P =0.004), and higher incidence of major adverse cardiovascular event (14.5% versus 6.3%, adjusted hazard ratio: 2.52, 95% CI: 1.12–5.63, P =0.025). In a 4-group classification according to Lp(a) and high-risk attributes, patients with high Lp(a) and ≥3 high-risk attributes had the highest risk of major adverse cardiovascular event (25.9%; overall P <0.001). Causal mediation analysis revealed that around 40% of the prognostic effect of Lp(a) was mediated by high-risk attributes. Lp(a) level is associated with coronary computed tomography angiography high-risk characteristics, including morphologic, physiologic, and inflammatory attributes as well as major adverse cardiovascular event. This effect is partly mediated by inflammation and vulnerable plaque. URL: https://www.clinicaltrials.gov; Unique identifier: NCT05323227 Download figure Download PowerPoint

Initial decrease in the lipoprotein(a) level is a novel prognostic biomarker in patients with acute coronary syndrome

Impact of serum lipoprotein (a) level on coronary plaque progression and cardiovascular events in statin-treated patients with acute coronary syndrome: a yokohama-acs substudy

Usefulness of Lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction

Impact of Lp(a) on lipid control in patients with acute coronary syndrome

Lipoprotein(a) as a novel biomarker for predicting adverse outcomes in ischemic heart failure

Long-Term Prognostic Value of Lipoprotein(a) in Symptomatic Patients with Nonobstructive Coronary Artery Disease.

Predictive value of lipoprotein(a) for assessing the prevalence and severity of lower-extremity peripheral artery disease among patients with acute coronary syndrome

Value of serum lipoprotein(a) measurement in patients with acute coronary syndrome

Serum Lipoprotein(a) Predicts 1-Year Major Cardiovascular Events in Patients after Percutaneous Coronary Intervention.

Impact of Baseline LDL-C and Lp(a) Elevation on Coronary Revascularization in Patients with Acute Coronary Syndrome One-Year after First Percutaneous Coronary Intervention

Abstract 10921: The Relationship Between Lipoprotein(a) and Cardiovascular Events in Chronic Kidney Disease Patients Hospitalized for Acute Coronary Syndrome

Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease

Lipoprotein(a), high-sensitivity C-reactive protein, and cardiovascular risk in patients undergoing percutaneous coronary intervention

Lipoprotein (A) is an Independent Also Age- and Sex-Specific Risk Factor of the Subsequent Cardiovascular Events in Patients with Acute Coronary Syndrome

Association of Lipoprotein (a) With Coronary-Computed Tomography Angiography–Assessed High-Risk Coronary Disease Attributes and Cardiovascular Outcomes

Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank

Percutaneous coronary intervention results in increases of lipoprotein(a) and oxidized lipoprotein(a) in patients with acute coronary syndrome

Lipoprotein(a), Immune Cells and Cardiovascular Outcomes in Patients with Premature Coronary Heart Disease

Prognostic value of elevated lipoprotein (a) in patients with acute coronary syndromes: a systematic review and meta-analysis

Lipoprotein(a) and Low-Molecular-Weight Apo(a) Phenotype as Determinants of New Cardiovascular Events in Patients with Premature Coronary Heart Disease

Coronary Artery Disease: Optimal Lipoprotein(a) for Survival—Lower Is Better? A Large Cohort With 43,647 Patients